Infosys Results + Wipro Contract

The board of Infosys Technologies will meet on 11 October 2007 to announce the Q2 results.

Wipro will provide integrated information technology (IT) services encompassing applications support, maintenance and infrastructure management services to Thames Water.

Meanwhile, yet another report suggests that Wipro’s business process outsourcing (BPO) arm is likely to buyout MarketRx, a pharma focused market analytics company. This acquisition will bolster Wipro BPO’s analytics practice, which at present accounts for less than 10% of its revenues. The New Jersey-headquartered $50-million MarketRx has over 25 clients, including Merck, Eli Lilly, Pfizer and Johnson & Johnson.

Accumulate Nagarjuna Construction – HDFC Sec

Nagarjuna Constructions Corp Ltd [NCCL] has six verticals comprising of Buildings and Housing, Transportation, Water and Environment, Electricals, Irrigation and Real Estate. Three verticals, Buildings and Housing, Transportation and Water and Environment together constitute 75% of the order backlog as well as turnover of NCCL.

NCCL has a well-diversified order book position, which is currently Rs 75.2 bn. The average execution period is 2.5 years, spread over more than 90 projects. Out of total order book, about 10% are overseas orders. Read Dalal Street News on Orders Secured by NCCL.

NCCL consolidated its real estate initiatives under NCC Urban Infrastructure (80% subsidiary, with promoters of NCC having 20%).NCCL in joint venture with Tishman Speyer & ICICI Ventures is planning to develop township on 400 acres site in Tellapur, Hyderabad and NCCL has a 26% stake in this project.

NCC has set up a separate company, Nagarjuna Infrastructure Holdings (NIH), to primarily focus on BOT related infrastructure projects. NCCL has an excellent track record of delivery among its peers portraying a reflection of its superior execution ability. US based Equity Fund, Blackstone ventures has bought 12.5% stake in the company.

NCCL’s foray into higher margin segments and the traction that its subsidiaries are expected to grow in the near future mean better visibility for revenues and profits going forward. On its fully diluted equity, it quotes about 18.5 – 19.5 times its FY09 earnings. HDFC recommends to accumulate NCCL in the Rs. 202 -224 band with an expected return of about 20% returns over the next 8-12 months.

SELL Educomp Solutions – High Risk

You are REading this first hereBreaking News:Citigroup in a research report has initiated coverage on Educomp Solutions with a AGGRESSIVE SELL rating and has categorized the stock in “HIGH RISK” vertical.

The crazy Indian market is ignoring expensive valuations and high risks in Educomp’s business model and aggressive accounting policy, in our view. We see 20% downside for the stock. Citi forecasts 102% revenue CAGR and 95% EPS CAGR over FY07-10 as Educomp penetrates beyond tier 1 & 2 cities. Stable margins as pressure in school ventures and the ICT business is countered by leverage in Smart_Class and MathGuru. There is high execution and regulatory risks in Edu-Infra and Edu-Manage.

Investors should note High valuations paid to acquire start-ups Edu-Infra and Edu-Manage; b) Reasons for exit taken by private equity firm just before IPO; and c) High regulatory risk in the K-12 business.

SELL with a target price of Rs 2,380, which is based on 35x FY09E fully diluted EPS, derived using the stock’s historical trading band. Target multiple of 35x is at 20% premium to the stock’s average historical valuation to factor in the company’s stronger growth prospects. It is supported by valuation multiples of other educational services companies in the Asia Pacific region. Target multiple of 35x is at a premium to the average valuation for Indian IT companies.

Panacea Biotec + Sadbhav Engineering

Panacea Biotec has inaugurated its greenfield construction vaccine formulation plant (VFP) in Baddi, Himachal Pradesh. The plant has been commissioned with several filling lines for bacterial and viral vaccines complying with WHO, cGMP norms for liquid vaccines in pre-filled syringes, liquid & lyophilized Vaccines in vials. The total production capacity of this facility is one billion doses per annum.

The company has also unveiled its new corporate identity on the occasion and the new identity displays a pole star and tag-line-innovation in support of life.

Sadbhav Engineering has been awarded the following project for contract price of Rs 245.24 crore for the work removal of over burden of first dig (solid) by hiring of HEMM such as excavators, dumpers, drills, dozers, graders and water tankers for composite work consisting of blast hole drilling, blasting, excavation, loading, transportation of broken rocks / soil / earth, dumping, spreading etc.

Complete including unloading spreading dozing, water sprinkling, grading etc. by mechanical means as per instruction of engineer in charge at specified places at Bina Extn OCP of Northen Coalfield (NCL).

Aggressively SELL Reliance Energy

Exclusive Live Coverage of EventsBreaking News: India’s Largest FII, Citigroup has recommended a SELL on Reliance Energy and has categorized the stock in “Low Risk” category. Stock Price target is Rs 510.

RELE shares have rallied up 118% over the past 5 months on expectations of blue-sky scenarios through capacity additions, EPC order wins and the value of CBM blocks. Even with extreme blue-sky scenario of 1] additional 25,000MW capacity in 7 years, 2] execution of EPC orders of Rs800bn to be executed over 7 years with EBITDA margins of 15%, 3] no fuel supply risks, 4] no execution risks, 5] generous multiples for valuations, 6] and 20% premium to our existing value of RELE (ex-cash) yields only Rs1,183/share. Citi reiterates a Sell on stock.

RELE has re-rated every time a project has been announced. It was expected that RELE would capitalize on the opportunities thrown up by the passing of the Electricity Act 2003 (EA03). Projects were announced from time to time, but 4 years have passed and RELE continues to have only 941MW of generation capacity and distribution licenses in Mumbai and Delhi.

12-month target price for Reliance Energy of Rs510 is based on RELE (ex net cash) value of Rs229 and net cash value of Rs281 (1.1x FY07E Net Cash/FD Share). RELE (ex net cash) would comprise Mumbai business value of Rs117, other power assets value of Rs27, EPC Business value of Rs65 and Delhi distribution value of Rs20. At target price of Rs510, RELE (ex Delhi) would trade at a P/E multiple of 10.1x FY09E.

Dalal Street Recommendation: We have recommended our clients to BUY PUT OPTIONS.

South Indian Bank banks on QIB issue

South Indian Bank has allotted 2 crore equity shares to qualified institutional buyers (QIB). The equity shares issued through qualified institutions placement (QIP) for Rs 10 each with a premium of Rs 153 per share. The purpose of QIP is to augment the capital base.

Kerala-based private-sector, SIB’s net profit rose 101.8% to Rs 30.37 crore on 41.8% growth in operating income to Rs 321.97 crore in Q1 June 2007 over Q1 June 2006.

SIB’s current equity share capital is Rs 70.41 crore. Face value per share is Rs 10.

Allotment status of Power Grid IPO can be now checked here.

1 66 67 68 69 70 173